| __timestamp | Alnylam Pharmaceuticals, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 50561000 | 122045000 |
| Thursday, January 1, 2015 | 41097000 | 144427000 |
| Friday, January 1, 2016 | 47159000 | 215003000 |
| Sunday, January 1, 2017 | 89912000 | 302238000 |
| Monday, January 1, 2018 | 74908000 | 408897000 |
| Tuesday, January 1, 2019 | 219750000 | 392755000 |
| Wednesday, January 1, 2020 | 492853000 | 520397000 |
| Friday, January 1, 2021 | 844287000 | 579775000 |
| Saturday, January 1, 2022 | 1037418000 | 667238000 |
| Sunday, January 1, 2023 | 1828292000 | 607521000 |
| Monday, January 1, 2024 | 2248243000 |
Cracking the code
In the ever-evolving landscape of biotechnology, Alnylam Pharmaceuticals and Supernus Pharmaceuticals have emerged as key players. Over the past decade, Alnylam has demonstrated a remarkable revenue growth trajectory, with a staggering increase of over 3,500% from 2014 to 2023. This growth is highlighted by a significant leap in 2023, where revenues soared to nearly $1.83 billion, marking a pivotal year for the company.
Conversely, Supernus Pharmaceuticals has shown steady progress, with revenues increasing by approximately 400% over the same period. Despite a slight dip in 2023, Supernus maintained a robust revenue stream, peaking at around $667 million in 2022.
This analysis underscores the dynamic nature of the pharmaceutical industry, where innovation and strategic investments drive financial success. As these companies continue to innovate, their financial trajectories offer valuable insights into the future of biotech.
Merck & Co., Inc. and Supernus Pharmaceuticals, Inc.: A Comprehensive Revenue Analysis
Revenue Showdown: Bristol-Myers Squibb Company vs Alnylam Pharmaceuticals, Inc.
Revenue Insights: Gilead Sciences, Inc. and Alnylam Pharmaceuticals, Inc. Performance Compared
Alnylam Pharmaceuticals, Inc. vs Exelixis, Inc.: Examining Key Revenue Metrics
Alnylam Pharmaceuticals, Inc. vs Halozyme Therapeutics, Inc.: Examining Key Revenue Metrics
Breaking Down Revenue Trends: Alnylam Pharmaceuticals, Inc. vs ImmunityBio, Inc.
Alnylam Pharmaceuticals, Inc. and Mesoblast Limited: A Comprehensive Revenue Analysis
Revenue Insights: Catalent, Inc. and Supernus Pharmaceuticals, Inc. Performance Compared
Ascendis Pharma A/S and Supernus Pharmaceuticals, Inc.: A Comprehensive Revenue Analysis
Revenue Showdown: PTC Therapeutics, Inc. vs Supernus Pharmaceuticals, Inc.
Perrigo Company plc and Supernus Pharmaceuticals, Inc.: A Comprehensive Revenue Analysis
Breaking Down Revenue Trends: ImmunityBio, Inc. vs Supernus Pharmaceuticals, Inc.